Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.66 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10945622 | 0.84 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP19A1POLBCTDSP1 | |
| SCHEMBL4290436 | 0.84 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1POLBKDM4E | |
| SCHEMBL17679983 | 0.81 | TSHR (0.60) | POLBCTDSP1TDP1TSHRKDM4E | |
| SCHEMBL1509681 | 0.79 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL23961241 | 0.78 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| Iodide SCHEMBL28192688 | 0.78 | CYP11B1 (0.97) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| Hydrochloric Acid SCHEMBL28135987 | 0.78 | CYP11B1 (0.97) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL28177559 | 0.77 | POLB (0.47) | CYP11B1CYP11B2POLBTSHRKDM4E | |
| SCHEMBL26613644 | 0.76 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 | |
| SCHEMBL13105206 | 0.76 | CYP11B1 (0.58) | CYP11B1CYP11B2CYP19A1POLBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62187403-A | — | — | None | — | — | JP | disclosed |
| US-6984646-B2 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALHCARE AG (DE) | 2006-01-10 | — | — | US | disclosed |
| EP-1412353-B1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1412353-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008413-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
| JP-S62187403-A | PLANT-GROWTH REGULATOR | RIKAGAKU KENKYUSHO | 1987-08-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | MAPK1, MAPK3, MAP3K1 | CYP11B1 245/4885CYP11B2 292/4885CYP19A1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.